Shareholder Alert: Ademi LLP investigates whether Aerie Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alcon

MILWAUKEE, Aug. 23, 2022 /PRNewswire/ -- Ademi LLP is investigating Aerie (NASDAQ: AERI) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. 

Click here to learn how to join the action: https://www.ademilaw.com/case/aerie-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Ademi LLP alleges Aerie's financial outlook and prospects are excellent and yet Aerie holders will receive only $15.25 per share representing an equity value of approximately $770 million. The transaction agreement unreasonably limits competing bids for Aerie by imposing a significant penalty if Aerie accepts a superior bid. Aerie insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Aerie's board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Aerie.

If you own Aerie common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/aerie-pharmaceuticals-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-aerie-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-transaction-with-alcon-301610717.html

SOURCE Ademi LLP